Stockscreener 앱 받기
0.3222
0.81%
0.0026
Bioatla Inc 주식(BCAB)의 최신 뉴스
Big Money Moves: Should you buy the dip on BioAtla IncJuly 2025 Update & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Brokerages Set BioAtla, Inc. (NASDAQ:BCAB) Target Price at $4.00 - Defense World
BioAtla (NASDAQ:BCAB) Coverage Initiated by Analysts at Rodman & Renshaw - Defense World
VIX Spike: Can BioAtla Inc deliver consistent dividendsJuly 2025 Review & Precise Entry and Exit Recommendations - baoquankhu1.vn
BioAtla Creates Super-Voting Share to Advance Reverse Split - The Globe and Mail
BioAtla stock initiated with Buy rating at Rodman & Renshaw - Investing.com
Why BioAtla Inc. stock remains resilientJuly 2025 Gainers & Real-Time Buy Signal Notifications - Улправда
BioAtla, Inc.Common Stock (NQ: BCAB - FinancialContent
Is BioAtla Inc. stock undervalued vs historical averages2025 Big Picture & Consistent Growth Stock Picks - ulpravda.ru
Is BioAtla Inc. stock attractive for hedge funds2025 Volatility Report & Daily Stock Trend Reports - Улправда
Is BioAtla Inc. stock dividend yield sustainable2025 Stock Rankings & Entry Point Confirmation Alerts - Улправда
What risks investors should watch in BioAtla Inc. stockEarnings Risk Report & Fast Entry Momentum Trade Alerts - Улправда
How BioAtla Inc. stock performs in rising dollar environmentMarket Volume Summary & Short-Term Trading Alerts - Улправда
How rising interest rates impact BioAtla Inc. stock2025 EndofYear Setup & Free Community Consensus Stock Picks - ulpravda.ru
Will BioAtla Inc. stock maintain momentum in 2025Volatility Index Analysis & Low Cost Portfolio Growth - ulpravda.ru
After-Hours Biotech Rally: Alumis, Genelux, Bright Minds, Context Therapeutics Post Big Gains - RTTNews
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Benzinga
BioAtla, GATC Health Advance Ozuriftamab Vedotin Into Phase 3 OPSCC Trial Via SPV Deal - Voice Of HealthCare
BioAtla Stock Slips Premarket After Early Pop As Investors Weigh $40M SPV Deal For Phase 3 Cancer Trial - Asianet Newsable
BioAtla stock slips premarket after early pop as investors weigh $40M SPV deal for phase 3 cancer trial - MSN
BioAtla’s Phase 3 Cancer Trial Is “AI-Backed”. Just Not in the Way You Think - AIM Media House
BioAtla and GATC Health to advance Oz-V in Phase III trial - Yahoo Finance
BioAtla announces $40 million oncology SPV investment deal - MSN
Bioatla stock rises after $40 million SPV deal to advance cancer drug - Investing.com Australia
BioAtla secures $40 million for phase 3 cancer drug development By Investing.com - Investing.com Nigeria
BioAtla (BCAB) Teams Up with GATC Health for $40M SPV Transaction to Tackle OPSCC with Oz-V - parameter.io
Bioatla stock rises after $40 million SPV deal to advance cancer drug By Investing.com - Investing.com South Africa
BioAtla Announces $40 Million Oncology SPV Investment Deal - TipRanks
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle Transaction to Advance Ozuriftamab Vedotin into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma - Investing News Network
BioAtla Signs Multiple Material Agreements - TradingView — Track All Markets
BioAtla secures $40 million for phase 3 cancer drug development - Investing.com India
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) - The Manila Times
BioAtla Secures $5 Million Initial Funding for Phase 3 Trial of Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma - Quiver Quantitative
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
BioAtla adjourns special meeting, stockholders approve share issuance By Investing.com - Investing.com Australia
BioAtla Stockholders Approve Share Issuance, Delay Reverse Split - TipRanks
BioAtla adjourns special meeting, stockholders approve share issuance - Investing.com India
4.73%
0.92%
자본화:
|
볼륨(24시간):